Drug Trial Radar · NCT05067582
A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder
Last checked: Nov 20, 2026Latest source record: Jul 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
58
Actual
Start
Jan 25, 2022
Primary completion
Jun 18, 2024
Study completion Jun 21, 2024
Sponsor
- Lead sponsor
- Yamo Pharmaceuticals LLCIndustry
- Sponsor type
- Industry
- First posted
- Oct 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate the efficacy, safety and tolerability of L1-79 in participants aged 12-21 years who have been diagnosed with ASD with a score of \>/= 70 on the Wechsler Abbreviated Scale of Intelligence (WASI-II), and a score of \>/= 4 on the Clinical Global Impression of Severity of Illness (CGI-S) weighted for socialization.
Conditions
- Autism Spectrum Disorder
- Autism
Interventions
L1-79Drug
tyrosine hydroxylase inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Vineland Adaptive Behavior Scale, Third Edition (Vineland-3), Responder AnalysisTime frame: Week 12
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Southwest Autism Research and Resource Center
Phoenix, Arizona
Thompson Autism Center CHOC
Orange, California
Cortica
San Rafael, California
Rush University
Chicago, Illinois
Thompson Center for Autism and Neurodevelopmental Disorders
Columbia, Missouri
Center for Autism and The Developing Brain
White Plains, New York
Ohio State University
Columbus, Ohio
Red Oak Psychiatry Associates
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.